# High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection

> **NCT02553083** · PHASE4 · UNKNOWN · sponsor: **Rabin Medical Center** · enrollment: 300 (estimated)

## Conditions studied

- Bacterial Infection Due to Helicobacter Pylori (H. Pylori)

## Interventions

- **DRUG:** Nexium 40 mg
- **DRUG:** amoxicillin 1.5 gr
- **DRUG:** doxycycline 200 mg
- **DRUG:** Nexium 20 mg
- **DRUG:** clarythromicin 500 mg
- **DRUG:** amoxicillin 1gr

## Key facts

- **NCT ID:** NCT02553083
- **Lead sponsor:** Rabin Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-10-22
- **Primary completion:** 2020-09
- **Final completion:** 2021-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2018-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02553083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02553083, "High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02553083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*